152 related articles for article (PubMed ID: 23793766)
1. [Non-invasive diagnosis bladder cancer: new molecular markers and future perspectives].
Musquera M; Mengual L; Ribal MJ
Arch Esp Urol; 2013 Jun; 66(5):487-94. PubMed ID: 23793766
[TBL] [Abstract][Full Text] [Related]
2. Urinary Biomarkers In Bladder Cancer.
Costantini M; Gallo G; Attolini G
Methods Mol Biol; 2021; 2292():121-131. PubMed ID: 33651357
[TBL] [Abstract][Full Text] [Related]
3. Bladder cancer biomarkers: current developments and future implementation.
Alvarez A; Lokeshwar VB
Curr Opin Urol; 2007 Sep; 17(5):341-6. PubMed ID: 17762628
[TBL] [Abstract][Full Text] [Related]
4. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
5. [The role of tumor markers in urologic consultation for screening, diagnosis, and follow-up of bladder cancer].
Lorenzo Gómez MF
Actas Urol Esp; 2003 Feb; 27(2):110-6. PubMed ID: 12731325
[TBL] [Abstract][Full Text] [Related]
6. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis.
Chou R; Gore JL; Buckley D; Fu R; Gustafson K; Griffin JC; Grusing S; Selph S
Ann Intern Med; 2015 Dec; 163(12):922-31. PubMed ID: 26501851
[TBL] [Abstract][Full Text] [Related]
7. Alternatives to cytology in the management of non-muscle invasive bladder cancer.
Amiel GE; Shu T; Lerner SP
Curr Treat Options Oncol; 2004 Oct; 5(5):377-89. PubMed ID: 15341676
[TBL] [Abstract][Full Text] [Related]
8. Current concepts of tumor markers in bladder cancer.
Droller MJ
Urol Clin North Am; 2002 Feb; 29(1):229-34. PubMed ID: 12109349
[TBL] [Abstract][Full Text] [Related]
9. [Urine cytology and new markers. Are there any advantages in terms of cost-effectiveness?].
Campodonico F
Urologia; 2013; 80 Suppl 21():7-10. PubMed ID: 23559136
[TBL] [Abstract][Full Text] [Related]
10. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
11. Bladder cancer. II. Molecular aspects and diagnosis.
Kausch I; Böhle A
Eur Urol; 2001 May; 39(5):498-506. PubMed ID: 11464029
[TBL] [Abstract][Full Text] [Related]
12. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
13. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
[TBL] [Abstract][Full Text] [Related]
14. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.
Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359
[TBL] [Abstract][Full Text] [Related]
15. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
Lodde M; Mian C; Mayr R; Comploj E; Trenti E; Melotti R; Campodonico F; Maffezzini M; Fritsche HM; Pycha A
Int J Urol; 2014 Oct; 21(10):968-72. PubMed ID: 24947145
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive diagnostic tests for bladder cancer: a review of the literature.
Bassi P; De Marco V; De Lisa A; Mancini M; Pinto F; Bertoloni R; Longo F
Urol Int; 2005; 75(3):193-200. PubMed ID: 16215303
[TBL] [Abstract][Full Text] [Related]
17. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions.
Ng K; Stenzl A; Sharma A; Vasdev N
Urol Oncol; 2021 Jan; 39(1):41-51. PubMed ID: 32919875
[TBL] [Abstract][Full Text] [Related]
18. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells.
Bonner RB; Hemstreet GP; Fradet Y; Rao JY; Min KW; Hurst RE
Cancer; 1993 Oct; 72(8):2461-9. PubMed ID: 8402463
[TBL] [Abstract][Full Text] [Related]
19. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
20. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
Zuiverloon TCM; de Jong FC; Theodorescu D
Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
